Skip to content
PubMed This is a summary of 101 peer-reviewed journal articles Updated
Ophthalmology

Euthyroid Graves orbitopathy: A Patient Guide

At a Glance

Euthyroid Graves orbitopathy can cause eye bulging, swelling, pain, and double vision even when thyroid hormone tests are normal. Care depends on whether inflammation is active or stable, with smoking cessation and long-term thyroid monitoring especially important.

Euthyroid Graves orbitopathy (EGO) is a unique and often misunderstood form of Thyroid Eye Disease where the immune system attacks the tissues behind the eyes even while the thyroid gland continues to function normally. For most patients, this means experiencing symptoms like eye bulging, swelling, or double vision while receiving blood test results that suggest nothing is wrong with their thyroid hormones. This happens because the antibodies responsible for the condition can target the receptors in the eye sockets independently of their effect on the thyroid gland itself [1][2].

The emotional impact of visible eye changes, double vision, and diagnostic uncertainty can be profound, and navigating the healthcare system to find the right specialists can be challenging. A supportive care team can help you navigate this.

The progression of this condition typically follows a predictable two-part timeline known as a biphasic course. It begins with an active inflammatory phase, during which the eyes may become red, painful, or increasingly prominent as the tissues behind them swell. Eventually, this active inflammation settles into a stable, inactive phase. Because the disease changes so significantly over time, medical care is tailored to the specific phase of the disease, the severity of the symptoms, and the urgency of the patient’s condition [3][4].

During the active phase, treatments are focused on calming the immune system and reducing swelling to prevent damage to the eyes and the optic nerve. Once the disease has moved into the inactive or stable phase, the focus shifts toward restorative and rehabilitative surgeries to address any permanent changes in appearance or vision. This phased approach ensures that elective surgical corrections are performed only when the “foundation” of the eye socket is stable and no longer changing. However, if severe, sight-threatening complications arise during the active phase, urgent emergency treatments or surgeries override this usual timeline [5][6].

Living with EGO requires a commitment to long-term vigilance and specific lifestyle adjustments. Because smoking is the single greatest risk factor for worsening the disease, absolute smoking cessation is the most powerful step a patient can take to protect their vision. Furthermore, even though thyroid levels may be normal today, the underlying immune activity means that lifelong, individualized monitoring is necessary to catch any future shifts in thyroid function. By working with a specialized multidisciplinary care team, patients can navigate these changes and move through the phases of the disease toward a stable and comfortable recovery [6][7].

Common questions in this guide

Can euthyroid Graves orbitopathy happen when thyroid tests are normal?
Yes. In this form of thyroid eye disease, immune activity affects tissues around the eyes even though thyroid hormone tests may be normal. Normal results do not rule out the condition, so ongoing thyroid monitoring may still be needed.
What symptoms can euthyroid Graves orbitopathy cause?
Symptoms can include eye bulging, swelling, redness, pain, and double vision. Visible changes and vision problems can affect comfort, daily activities, and emotional well-being.
How do the active and inactive phases of the disease differ?
The active phase is when inflammation and swelling are changing or worsening, often causing redness, pain, or more prominent eyes. It eventually settles into an inactive, stable phase. Treatment is chosen based on the phase, severity, and whether vision is at risk.
What treatments are used for euthyroid Graves orbitopathy?
During active disease, care focuses on calming immune activity and reducing swelling to protect the eyes and optic nerve. After the disease is stable, restorative or rehabilitative surgery may address lasting changes in appearance or vision. Sight-threatening complications require urgent treatment and can override the usual timeline.
Does smoking affect euthyroid Graves orbitopathy?
Yes. Smoking is described as the greatest risk factor for worsening the disease, so stopping smoking is the most important lifestyle step for protecting vision. Ask your healthcare team about quit-smoking resources and support.
What tests help evaluate euthyroid Graves orbitopathy?
A clinician may use an eye examination, imaging, and other targeted testing to support or revisit the diagnosis. Because thyroid hormone results can be normal in euthyroid Graves orbitopathy, testing is interpreted alongside eye findings and the patient's course.
How should euthyroid Graves orbitopathy be monitored over time?
A long-term plan should include individualized monitoring of thyroid function, even if current levels are normal, because thyroid function can change over time. Follow-up with a specialized multidisciplinary team can help track the eye disease, its phase, and any urgent vision problems.

Get notified when new evidence is published on Euthyroid Graves orbitopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (7)
  1. 1

    Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature.

    Muñoz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E, et al.

    Systematic reviews 2020; (9(1)):201 doi:10.1186/s13643-020-01459-7.

    PMID: 32873324
  2. 2

    Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

    Marinò M, Ionni I, Lanzolla G, et al.

    Journal of endocrinological investigation 2020; (43(4)):401-411 doi:10.1007/s40618-019-01141-3.

    PMID: 31691261
  3. 3

    Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors.

    Bartalena L, Gallo D, Tanda ML, Kahaly GJ

    Ophthalmic plastic and reconstructive surgery 2023; (39(6S)):S2-S8 doi:10.1097/IOP.0000000000002467.

    PMID: 38054980
  4. 4

    Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.

    Gupta V, Hammond CL, Roztocil E, et al.

    Survey of ophthalmology 2022; (67(3)):858-874 doi:10.1016/j.survophthal.2021.08.010.

    PMID: 34487739
  5. 5

    Quantitative Assessment of Orbital Decompression Surgery Using Photogrammetric Stereoimaging.

    Murta F, Hyer JN, Haridas A, et al.

    Ophthalmic plastic and reconstructive surgery 2021; (37(5)):420-423 doi:10.1097/IOP.0000000000001885.

    PMID: 33237668
  6. 6

    The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.

    Bartalena L, Kahaly GJ, Baldeschi L, et al.

    European journal of endocrinology 2021; (185(4)):G43-G67.

    PMID: 34297684
  7. 7

    Euthyroid graves' ophthalmopathy in a Chinese population: A cross-sectional follow-up study.

    Lai KK, Ali Abdulla Aljufairi FM, Sebastian JU, et al.

    European journal of ophthalmology 2024; (34(5)):1432-1437 doi:10.1177/11206721241229470.

    PMID: 38444235

This page is for informational purposes only and does not constitute medical advice. Your eye and thyroid care specialists can interpret your test results and advise you about your disease phase and treatment.